medigraphic.com
ISSN 1028-4818 (Electronic)

2017, Number 1

<< Back Next >>

Mul Med 2017; 21 (1)

Soft-tissue alveolar sarcoma. Presentation of a case

Herrera PB, Mantilla VY, Brizuela ZL

Language: Spanish
References: 19
Page: 172-182
PDF size: 314.02 Kb.


ABSTRACT

Introduction: soft-tissue alveolar sarcoma is a rare neoplasm with a poor prognosis and uncertain histogenesis, characterized by a characteristic histological image, specific molecular alterations and a unique and distinctive clinical behavior.
Presentation of a case: we studied an 18-year-old woman who, at 30 weeks of pregnancy, was diagnosed with a soft-tissue tumor that interested the right gluteal region.
Discussion: it turned out to be an alveolar sarcoma, with the aggravating of gestation and an accelerated growth of the same. We emphasize the image studies that are performed highlighting ultrasound for its advantages.
Conclusions: the pregnancy was successfully completed with intervention at 34 weeks, treatment with chemotherapy and stabilization of the disease was established.


REFERENCES

  1. Kransdorf M, Murphey M. Origin and classification of soft tissue tumors. En: Imaging of Soft Tissue Tumors. 2ª ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1-5.

  2. Kransdorf M, Murphey M. Soft tissue tumors in a large referral population: prevalence and distribution of diagnoses by age, sex and location. En: Imaging of Soft Tissue Tumors. 2ª ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 6-37.

  3. Fornage B. Soft tissue masses, the underutilization of sonography. Semin in Musculoskelet Radiol [Internet] 1999 [citado 16 Oct 2016]; 3(2): 115-34. Disponible en: https://www.thieme-connect.com/DOI/DOI?10.1055/s-2008-1080056.

  4. Weatherhall P. Imaging of muscle tumors. Semin in Musculoskel Radiol [Internet]. 2000 [citado 16 Oct 2016]; 4(4): 435-58. Disponible en: https://www.thieme-connect.com/DOI/DOI?10.1055/s-2000-13170.

  5. Jacobson J. Musculoskeletal ultrasound and MRI: which do I choose? Semin in Musculoskelet Radiol [Internet]. 2005 [citado 16 Oct 2016]; 9(2): 135-49.Disponible en: https://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-872339.

  6. Van Holsbeeck, Introcaso J. Sonography of the dermis, hypodermis, periostium and bone. En: Musculoskeletal Ultrasound. 2ª ed. St. Louis: Mosby Inc; 2013. p. 371.

  7. Hodler J, Yu J, Steinert H, Resnick D. MR Imaging versus alternative imaging techniques. Magn Reson Imaging Clin N Am. 1995 Nov; 3(4):591-608.

  8. Murphey M. World Health Organization classification of bone and soft tissue tumors: modifications and implications for radiologists. Semin Musculoskelet Radiol [Internet]. 2007 [citado 16 Oct 2016]; 11(3): 201-14. Disponible en: https://www.thieme-connect.com/DOI/DOI?10.1055/s-2008-1038310.

  9. Resnick D, Niwayama G. Soft Tissues. En: Diagnosis of bone and joint disorders. 3ª ed. Philadelphia: W.B. Saunders Company; 1995. p. 4491-622.

  10. Kransdorf M, Murphey M. Benign fibrous and fibrohistocytic tumors. En: Imaging of Soft Tissue Tumors. 2ª ed. Philadelphia: Lippincott Williams & Wilkins; 2006.p. 189-256.

  11. Fornage B. The case or Ultrasound of muscles and tendon. Semin in Musculoskelet Radiol [Internet]. 2000 [citado 16 Oct 2016]; 4(4): 375- 91. Disponible en: https://www.thieme-connect.com/DOI/DOI?10.1055/s-2000-13168.

  12. Ogose A, Yazawa Y, Ueda T. Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology. 2003; 65(1): 7-13.

  13. Lazar AJ, Lahat G, Myers SE, Smith KD, Zou C, Wang WL, et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical

  14. study utilizing tissue microarray. Histopathology [Internet]. 2009 [citado 16 Oct 2016]; 55(6): 750-5. Disponible en: http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2009.03436.x/full.

  15. Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res [Internet]. 2007 [citado 16 Oct 2016]; 67(3): 919-29. Disponible en: http://cancerres.aacrjournals.org/content/67/3/919.long.

  16. Azizi AA, Haberler C, Czech T. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol. 2006; 7(6): 521-3.

  17. Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, et al. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol [Internet]. 2009 [citado 16 Oct 2016]; 31(8): 561-70. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784654/pdf/nihms-118018.pdf

  18. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cáncer Res [Internet]. 2009 [citado 16 Oct 2016]; 15(3):1096-104. Disponible en: http://clincancerres.aacrjournals.org/content/15/3/1096.long.

  19. Liebl LS, Elson F, Quaas A, Gawad KA, Izbicki JR. Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res [Internet]. 2007 [citado 16 Oct 2016]; 27(4c): 2897-902. Disponible en: http://ar.iiarjournals.org/content/27/4C/2897.long.




2020     |     www.medigraphic.com